Maximum Views Reached

You have reached the maximum number of Guideline views for today. By creating a free account, you can increase your number of complimentary daily views.

To view this Guideline, please log in to your account. If you do not have an account, you can create one for free by clicking the button below.

Prevention, Detection, and Management of Respiratory Depression Associated with Neuraxial Opioid Administration

Publication Date: March 1, 2016

Last Updated: March 14, 2022

Summary of Recommendations

Identification of Patients at Increased Risk of Respiratory Depression

Conduct a focused history and physical examination before administering neuraxial opioids.

Direct particular attention toward signs, symptoms, or a history of sleep apnea, co-existing diseases or conditions (e.g., diabetes, obesity), current medications (including preoperative opioids), and adverse effects after opioid administration.
A physical examination should include, but is not limited to, baseline vital signs, airway, heart, lung, and cognitive function.

6731

Overview

Title

Prevention, Detection, and Management of Respiratory Depression Associated with Neuraxial Opioid Administration

Authoring Organization